BCR/ABL p210 (major) reflex to ABL Kinase Muation Panel
Unique Identifier:
ML-H008
Name on Requisition:
BCR/ABL Major Quantitative reflex to ABL Kinase Mutation
Product Line:
HEME
Panel Group:
PCR/NGS
Panel Name:
PCR–CML
Methodology
Molecular
PCR, NGS
Test Description and clinical significance
Genes
BCR/ABL1 (t(9;22) Major (p210) breakpoints & ABL Kinase gene
Disease:
B-cell lymphoblastic leukemia/lymphoma, and acute myeloid leukemia ,MPN
A polymerase chain reaction that is recommended for identification of BCR-ABL1 fusion genes is used for diagnosis and ongoing therapeutic monitoring for CML. This test acess the gene mutations that may interfere with the effectiveness of tyrosine kinase inhibitor (TKI) therapy and to determine management strategy when the BCR/ABL major mutation is negative.
Specimen Requirements
Preparation:
PB, BM, RNA
Collection:
3ml EDTA, citrate (ACD) or Heparinized whole blood or bone marrow aspirates are transported at room temperature, received with 96 hr, refrigerated are stable for a week from the date of collection, Extracted RNA; a minimum volume of 20 μl at 100ng/μl
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Clotted peripheral blood or bone marrow. Peripheral blood or bone marrow older than a week. Leukophoresis products. Improperly labeled specimens. Improperly stored RNA.
Storage & Transport
Blood or bone marrow specimens should be kept at room temperature and preferably received within 96 hrs of drawing, Previously extracted RNA is acceptable if stored at appropriate temperature short term at -20oC (up to two weeks) or long term at -80oC and should be transported on dry ice.
CPT(s)
81206, 81170
New York Approved
Yes
TAT
3 to 5
Requisition Type
Heme
Levels of Service
Full
DexS Code
NONE
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
